This recombinant monoclonal antibody is a research-grade biosimilar to Besilesomab, targeting CEACAM8 (CD66b), a glycosylphosphatidylinositol-anchored glycoprotein of the carcinoembryonic antigen family. CEACAM8 is specifically and abundantly expressed on the surface of human granulocytes, particularly neutrophils, where it plays a role in cell adhesion, activation, and migration during inflammatory responses. This target serves as a reliable marker for granulocyte identification and has been implicated in various inflammatory conditions, infections, and immune-mediated disorders where neutrophil recruitment and activity are critical pathological features.
Besilesomab is a murine IgG1 monoclonal antibody that was developed for imaging inflammatory lesions and infectious foci through its specific binding to granulocyte CEACAM8. This biosimilar provides researchers with a valuable tool for investigating neutrophil biology, studying granulocyte-mediated inflammatory processes, and exploring CEACAM8 function in immune regulation. It enables detailed examination of neutrophil behavior in disease models and facilitates research into inflammatory and infectious disease mechanisms.
Email: support@cusabio.com
Distributors Worldwide